This invention relates in general to a flow delivery system that delivers an aqueous solution containing a biomaterial or a mixture of a biomaterial and a biocompatible fluid lubricant into a body, and in particular to such a system that includes a filter that breaks up or downsizes particles of the biomaterial that are larger than desired (e.g., a relatively large agglomerated mass of the particles) for more effective delivery of the aqueous solution into the body.
Medical procedures often involve the non-surgical implanting of biomaterials into the body. An example is the injecting of a dermal filler material such as collagen through the use of a syringe and needle system. The biomaterial can be solid and load-bearing and is typically suspended as an aqueous solution of the biomaterial particles. The solution is then injected with a syringe through a needle. For precise placement of materials into the facial dermis, a very fine needle, e.g., 27 gauge (0.0075″ inside diameter or ID) to 30 gauge (0.0055″ ID), is preferred. These relatively small ID needles limit the size of the suspended particles that may pass through the needle orifice. The size of the particle will typically range between 1-20 microns (0.001 mm-0.02 mm) in length and less than 20 microns (0.02 mm) in width. It has been determined that larger particles are desirable in some situations, such as the containment of time release medication. The larger particles pose a problem when used with the smaller needles required in the facial derma. The larger particles can bridge or agglomerate resulting in clogging of the small orifice needle. Larger particles also result in a greater amount of force needed to translate the syringe plunger. The higher force may cause the surgeon to tremble and slight perturbations of the hand could result in scaring of the patient. Therefore, it is desirable to have applied forces equivalent to a low viscidity Newtonian fluid.
Other applications for implanting a biomaterial into the human body include use of the biomaterial as a bulking or augmenting agent in internal body tissue, such as the tissue that defines various sphincters, for example, in the urinary tract (specifically, in the urinary outflow of the bladder into the urethra) or in the lower esophageal area connecting the esophagus to the stomach. The malfunctioning of these sphincters is usually in the form of improper or incomplete closure of the sphincters, which leads to medical conditions such as urinary incontinence and gastroesophageal reflux disease (GERD) or heartburn, respectively. Treatment of these medical conditions may include injections of a viscous material dispersed in a solution, such as collagen, in the vicinity of the associated sphincter to augment or bulk up and fortify the tissue and thereby assist in the adequate closure of the corresponding sphincter for re-establishment of normal sphincter control. Still other applications for implanting a biomaterial such as collagen into the human body include various other body passages and tissues; for example, for correcting wrinkles not only in the facial denim but in other areas of the body as well.
In these applications it is known to inject the biomaterial, typically suspended in an aqueous solution, into the human body through use of a syringe together with an elongate needle and/or catheter. This type of flow delivery system may be used as a standalone device or in combination with an appropriate medical instrument, such as a cystoscope, endoscope or gastroscope, which are utilized to view the tissue in the affected area. However, as the length of the elongate needle and/or catheter increases, the amount of force required to properly deliver the suspended mass aqueous solution of biomaterial to the desired body tissue area also increases. With known flow delivery systems, this increased amount of required force can cause problems both with the extrusion of the biomaterial through the flow delivery system and also with the intrusion of the biomaterial into the tissue. Oftentimes poor intrusion into the body tissue is the result of poor extrusion through the flow delivery system.
There has been substantial research and experimentation in various chemical compositions to reduce plunger force in a syringe and needle and/or catheter flow delivery system. An area commonly researched is the ability to introduce lubricity between the particles through use of an aqueous suspension of a particulate biocompatible material and a biocompatible fluid lubricant. The biomaterial and lubricant are typically combined in a manner that results in a homogenous mixture. It is believed that the lubricant enhances flow in part by preventing particle to particle contact. See, e.g., U.S. Pat. No. 4,803,075. However, a disadvantage of the addition of the lubricant is that it reduces the content of the active component in solution.
What is needed is an improved flow delivery system for implanting a biomaterial into the human body, where the system includes a filter that breaks up or downsizes particles of the biomaterial that are larger than desired, to achieve a more effective delivery of the aqueous solution into the body.
Briefly, according to an aspect of the present invention, a flow delivery system includes a syringe and a needle and/or a catheter that delivers an aqueous solution of a material, such as a biomaterial or a mixture of a biomaterial and a biocompatible fluid lubricant, into a body, preferably at a constant applied force. Preferably, a filter is located within the body of the syringe. The filter includes a plurality of openings, each of a predetermined size. As the aqueous solution containing the suspended biomaterial particles travels through the body of the syringe under an applied force, the solution encounters the openings in the filter which break up or downsize any particles of the biomaterial within the solution that are larger than the size of the openings. At the same time, the openings in the filter allow any particles of the biomaterial that are smaller than the size of the openings to pass without any downsizing. The size of the openings in the filter may vary and preferably is selected in dependence on the size of the opening or orifice in the needle and/or catheter. The downsized particles then pass together with any other non-downsized particles in a relatively unobstructed manner through the needle and/or catheter and its orifice and into the body.
The present invention has utility in that the filter breaks up any agglomerated biomaterial particle matter or mass into smaller particles of a specific size (i.e., that of the openings in the filter). This reduces the resistance to the flow of the aqueous solution through a flow delivery system that includes the filter, which also reduces the amount of force necessary to transport and expel the aqueous solution through the system and into a body.
These and other objects, features and advantages of the present invention will become more apparent in light of the following detailed description of preferred embodiments thereof, as illustrated in the accompanying drawings.
In the figures, like reference numerals refer to like elements.
The flow delivery system 30 may include the syringe 12, plunger 14 and needle and/or catheter 20, along with some or all of the other structural components of the known flow delivery system 10 of
In operation, the filter 40 within the flow delivery system 30 breaks up any agglomerated biomaterial particle matter or mass within the aqueous solution into smaller particles of a specific size or smaller (i.e., that of the openings 44 in the filter 40 of
The flow delivery system 30 of the present invention has been described for use with a conventional syringe and needle/catheter configuration that also contains a plunger 14 to supply a force to push the aqueous solution through the syringe 12 and out of the needle/catheter 20. However, the broadest scope of the present invention is not limited as such. The plunger 14 may be omitted and other means for forcing the aqueous solution through the syringe 12 may be utilized such as, for example, an acoustic transducer. Also, the syringe 12 may omit the plenum 24 (
Although the present invention has been illustrated and described with respect to several preferred embodiments thereof, various changes, omissions and additions to the form and detail thereof, may be made therein, without departing from the spirit and scope of the invention.
This patent application is a continuation of PCT Patent Application No. PCT/US08/78098 filed Sep. 29, 2008, which claims priority from U.S. patent application Ser. No. 60/975,841 filed Sep. 28, 2007, both of which are hereby incorporated by reference.
Number | Date | Country | |
---|---|---|---|
60975841 | Sep 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US08/78098 | Sep 2008 | US |
Child | 12749079 | US |